While nanocarriers can be engineered to recognize molecular markers on myeloma cells, such as CD38, CD1, BCMA, and CD138, tumor heterogeneity and the dynamic nature of these markers can complicate this strategy [110]. Here, TNFRSF17 is linked to plasma cell myeloma.